Rab8a GTPase is associated with the dynamic regulation of membrane protrusions in polarized cells. Rab8a is one of several Rab-family GTPases that are substrates of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that is linked to inherited Parkinson's disease. Rab8a is phosphorylated at T72 (pT72) in its switch 2 helix and the post-translational modification facilitates phospho-Rab8a (pRab8a) interactions with RILPL2, which subsequently regulates ciliogenesis. Here we report the crystal structure of pRab8a in complex with the phospho-Rab binding domain of RILPL2. The complex is a heterotetramer with RILPL2 forming a central -helical dimer that bridges two pRab8a molecules. The N-termini of the -helices cross over to form an X-shaped cap (X-cap) that enables electrostatic interactions between Arg residues from RILPL2 and the phosphate moiety from pT72. RILPL2 residues in the X-cap that are critical for pRab8a binding are conserved in the RILP family of effector proteins. We find that JIP3 and JIP4 also interact specifically with LRRK2-phosphorylated Rab10, suggesting a general mode of recognition for phosphorylated Rab GTPases by phospho-specific effectors.
Introduction
Parkinson's disease (PD) is a disorder of the central nervous system that manifests as a progressive degeneration of motor mobility, loss of balance, and tremors. Features of the pathology include loss of dopaminergic neurons in the midbrain and the presence of protein aggregates termed Lewy bodies, composed mainly of -synuclein, in surviving neurons [1] . About 10% of cases have a genetic basis, with the most common gene being the Leucine-Rich Repeat Kinase 2 (LRRK2) [2] , . The gene product is a 2,527-residue (286kDa) protein with multiple domains belonging to the ROCO family that is involved in regulation of autophagy, mitochondria, and Golgi dynamics [3] . The kinase domain, located near the C-terminus, phosphorylates itself and other proteins at serine/threonine residues [2, 4, 5] . Preceding the kinase domain, there is a Ras-like ROC domain (Ras of complex) followed in tandem by a COR domain (C-terminal of Ras). The ROC domain binds nucleotides (GTP/GDP) and is distantly related to the Rab family of small GTPases. The ROC-COR tandem domains regulate LRRK2 activity and numerous missense mutations have been localized to these regulatory and kinase domains [6] [7] [8] . In addition to early onset forms of PD associated with autosomal dominant mutations, LRRK2 is also linked to late-onset sporadic cases of PD [9] .
Insight into LRRK2 functions has progressed significantly with the finding that a subset of small GTPases that include Rab8 and Rab10 are physiological substrates of the enzyme [5, 10] . Rabs comprise the largest group (~70 members) of the Ras superfamily, and they cycle between an active GTP-bound and inactive GDP form to regulate membrane trafficking in eukaryotic cells [11] . The nucleotide-bound state of Rabs is regulated by GTPase activating proteins (GAPs) and GTP/GDP exchange factors (GEFs), and active Rabs migrate to distinct sub-cellular compartments where they recruit cytosolic effector proteins. The 'switch' regions of Rabs, termed switch 1 and 2, undergo local conformational changes that enable recruitment of GTP-specific effectors, which subsequently control processes such as vesicle formation/fusion, motility, and other aspects of cell dynamics [12] . LRRK2 phosphorylates Rab8a at T72 and Rab10 at T73, conserved threonine residues located on the -helical switch 2 region. This posttranslational modification modulates interactions between Rabs and their binding partners [5, 13] . For example, it inhibits interaction with some effectors such as Rab GDP dissociation inhibitors (GDIs) and Rabin-8, a GEF for Rab8a [5] . LRRK2 phosphorylation of Rab8a and Rab10 also promoted interaction with two poorly studied scaffolding proteins termed RILPL1 (Rab interacting lysosomal like protein 1) and RILPL2 [13] , that were previously implicated in regulating ciliogenesis [14] . RILPL1 and RILPL2 belong to the RILP (Rab interacting lysosomal protein) family of effector proteins [15] . Unlike RILPL1 and RILPL2, RILP was not observed to interact with LRRK2 phosphorylated Rab8a or Rab10 [13] , however, it is a known effector for Rab7a
GTPase [16] . A recent study has suggested that RILP may bind more strongly to Rab7a phosphorylated at the equivalent site to LRRK2 by the related LRRK1 kinase [17] .
Cellular studies have confirmed that LRRK2 blocks ciliogenesis by phosphorylating Rab8a and Rab10 and promoting RILPL1 interaction [18] . RILPL1 and RILPL2 are homologous and were shown to interact with LRRK2 phosphorylated Rab8a and Rab10 via a C-terminal phospho-Rab binding domain that encompasses a conserved region of the protein. This region of the protein is also known as the RILP homology domain 2 (RH2) and encompasses residues 291-356 on RILPL1 and residues 130-201 on RILPL2. RILPL1 and RILPL2 also contain an N-terminal RH1 domain that binds to the globular tail domain (GTD) of myosin Va [19] .
Upstream of LRRK2 it has been shown that Rab29 recruits LRRK2 to the Golgi and activates the kinase, leading to an enhanced phosphorylation of downstream Rab GTPases, as well as increased autophosphorylation [20] [21] [22] . Rab32 is not a target for the kinase but it interacts with LRRK2 and regulates its sub-cellular localization [23] . Thus, LRRK2 is at the center of a Rab signaling cascade that is a key to understanding the biological functions of LRRK2 and its relationship to PD. Here we describe the crystal structure of T72 phosphorylated GTP bound form of Rab8a in complex with a minimal phospho-Rab binding domain of RILPL2 at 1.8 Å resolution. The structure reveals that the phosphothreonine (pT72) is recognized by a conserved arginine from the RILP family of proteins, suggesting a general mechanism for phospho-specific recognition of effectors by Rab GTPases.
Results and Discussion
Overall structure of pRab8a:RILPL2 complex For these studies we utilized a mutant of the globular G-domain of Rab8a (Q67L, residues 1-181) that binds GTP constitutively. Full-length RILPL2 complexes failed to crystallize, but the phospho-Rab binding domain of RILPL2 (residues 129 to 165) yielded crystals in complex with pRab8a. This region has an N-terminal hexahistidine tag and is the minimal fragment with high sequence similarities to all members of the RILP effector family. The complex of pRab8a(GTP):RILPL2 is organized as a heterotetramer in the asymmetric unit ( Fig 1A and 1B) , with a central parallel -helical dimer of the phospho-Rab binding domain of RILPL2 bridging two molecules of pRab8a via hydrophobic and polar interactions. Both molecules of pRab8a in the complex have GTP in the nucleotide pocket and their switch 1 and 2 conformations resemble the structure of active Rab8a
[PDB code 4lhw [24] ]. Each pRab8a molecule interacts with both -helices of the effector, burying approximately 625 Å 2 of surface area at each interface. The dual helical interactions are restricted to the N-terminal segment of RILPL2. As the coiled coil extends toward the C-termini, a single -helix interacts with each Rab monomer by interfacing with switch 1 and strand 2 of the interswitch region ( Fig 1C) . The topology of the complex on Golgi membranes would be consistent with the N-terminus of RILPL2
(1-128) oriented above the complex in the orientation shown in Fig 1A to enable interactions with the GTD of myosin Va. The C-termini of pRab8a (177-207) and RILPL2 (160-211) would reside proximal to the membrane, as indicated with dashed lines following helix 5 of pRab8a. In the ensuing discussions, the acronyms 'RL2' and 'R8' will be used in superscript format to denote RILPL2 and Rab8a residues, respectively.
The affinity of the interaction between pRab8a and the phospho-Rab binding domain (129-165) of RILPL2 was evaluated by isothermal titration calorimetry ( Fig 1D, left) .
The experiment revealed a K d = 3.3M (±0.5) for the interaction, which indicates a relatively weak affinity that is similar to other physiological Rab:effector complexes [12] .
There were no detectable interactions between non-phosphorylated Rab8a(GTP) and RILPL2 ( Fig 1D, right) .
Phosphorylated switch 2 of Rab8a interacts with an 'X-cap' region of RILPL2
The N-termini of the RILPL2 dimer (N129 RL2 -T134 RL2 ) cross over in an extended conformation preceding the first -helical turn, forming an X-shaped cap (X-cap) over the coiled coil (Figs 2A and 2B ). This X-cap contains two conserved arginines (R130 RL2 , R132 RL2 ) that previous mutagenesis analysis showed were required for interaction with pRab8a [13] . Intimate contacts within the X-cap include reciprocal backbone hydrogen bonds between residues R132 RL2 -Phe133 RL2 that resemble a short anti-parallel -sheet ( Fig 2B) . The phosphate moiety from pT72 interacts with the guanidino group (NH1/NH2) of R132 RL2 on both sides of the symmetric complex, with O/N distances between 2.5-2.9 Å ( Fig 2C) . Thus, R132 RL2 binds directly to the phosphorylated threonine, and this residue is conserved in the RILP family of effectors ( Fig 4C) . In contrast to these direct electrostatic and hydrogen-bonding interactions, the side chain of R130 RL2 is relatively disordered and more distant from pT72 (>6 Å). An electrostatic surface map of RILPL2 reveals the strongly positive charges at the X-cap that enable recognition of pRab8a ( Fig 2D) . In addition to electrostatic contacts, the X-cap residue F133 RL2 contributes to a complementary hydrophobic interface with F70 R8 and I73 R8 from switch 2 ( Fig 2B) . The side chain of T134 RL2 acts as a capping residue by nucleating the -helix via a hydrogen bond (3.2 Å) to the backbone NH of E137 RL2 . Therefore, the term X-cap is appropriate for this region of RILPL2.
Mutational analyses of the binding interface
The contribution of RILPL2 residues to complex formation with pRab8a was evaluated by mutagenesis.
LRRK2-phosphorylated Rab8a was subjected to coimmunoprecipitation studies in cells using wild type and mutant forms of full length RILPL2. For these studies a pathogenic LRRK2[R1441G] mutant was overexpressed to ensure maximal phosphorylation of Rab8a. We also treated cells with and without a potent and selective LRRK2 inhibitor termed MLi-2 [25] for 90 min to induce dephosphorylation of Rab8a and, therefore, block association with RILPL2 (Figs 3 and EV3A-B). These results revealed that all mutations of R132 RL2 , which directly interacts with pT72, abolished the interaction with pRab8a in cells. The exquisite specificity of this contact is reflected by the R132K RL2 mutation, which was sufficient to abolish the interaction (Fig 3) . Mutation of K149 RL2 -which forms a salt bridge with D44 R8 (switch 1) -also abolishes the interaction between RILPL2 and pRab8a. This interaction, as well as hydrophobic packing of I41 R8 against the RILPL2 -helical dimer, presumably encodes GTP-dependent switch 1 specificity. Modest effects were observed with mutations of R139 RL2 and L135 RL2 , which form contacts with switch 2 adjacent to the R132 RL2 :pT72 interaction. L135 packs against the -branched methyl substituent of pT72, while R139 forms a hydrogen bond with the backbone carbonyl oxygen of pT72
(Figs 2A and 2C).
One apparent inconsistency between the structure and the mutagenesis experiments is the contribution of R130 RL2 toward complex formation. Mutational studies reveal that R130Q RL2 (Fig 3) , R130E RL2 ( Fig EV3A) and R130A RL2 ( Fig EV3A) severely compromise the interactions with pRab8a. As previously mentioned, the side chain of R130 RL2 is relatively disordered and lies more than 6 Å away from pT72.
However, modeling of alternate conformations of the side chains brings the guanidino group to within 5 Å of the phosphate on both interfaces. Thus, a reasonable explanation is that Arg130 RL2 contributes to pT72 through long-range electrostatic interactions with the phosphate.
GTP dependency of the interaction between pRab8a and RILPL2
The GTP dependency of pRab8a interactions with full-length RILPL2 were investigated using in vitro pulldowns ( Fig 4A) . The interaction with RILPL2 in vitro is dependent on both the GTP conformation and phosphorylated T72 for Rab8a. Non-phosphorylated
Rab8a and pRab8a(GDP) did not interact measurably with RILPL2.
To further investigate the GTP dependency in cells, we co-expressed RILPL2 with either wild type Rab8a, Rab8a[Q67L] (GTP trapped conformation) or Rab8a[T22N]
(GDP bound conformation) in the presence of pathogenic LRRK2[Y1699C] to induce maximal Rab8a phosphorylation ( Fig 4B and EVFig4 ). For these experiments, cells were treated ± LRRK2 MLi-2 inhibitor and phosphorylation of wild type and mutant Rab8a
was assessed in cell extracts as well as RILPL2 immunoprecipitates. Strikingly, this revealed that both cell lysates and immunoprecipitates of the pRab8a[Q67L] GTP locked mutant, MLi-2 failed to induce dephosphorylation of Rab8a over a 90 min period (Fig 4) .
We interpret this result to indicate that the pRab8a[Q67L] GTP locked conformation remains stably associated with RILPL2 over this period and is thus protected from dephosphorylation by cellular phosphatases. In comparison, MLi-2 treatment induced significant dephosphorylation of wild type Rab8a that is presumably interconverting between the GTP and GDP conformation ( Fig 4) . The GDP-locked conformation of Rab8a[T22N] was expressed at much lower levels in cell than wild type or Rab8a[Q67L]
(EVFig4). Nevertheless, no association of RILPL2 with, Rab8a[T22N] was observed.
Furthermore, phosphorylation of Rab8a[T22N] was not observed which is consistent with the GTP bound conformation being regulated by LRRK2.
X-cap binding to phosphorylated switch 2 may be a general mode of recognition
The structure of the Rab binding domain of RILP bound to Rab7 has been determined previously [ Fig 5A ; [26] ]. Similar to RILPL2, the effector forms a parallel coiled coil that binds two Rab7 molecules as a heterotetrameric complex. RILP does not have an 'Xcap' at the N-terminusthe first few residues in the structure beginning at C241 are disordered until the start of the core helix at Glu246 (Figs 5A-B). Following helix 1 of the Rab binding domain of RILP, a loop brings a second anti-parallel helix 2 back toward the 1 dimer and is stabilized by hydrophobic interactions. Helix 2 is unlikely to be conserved in RILPL1/2 given a string of glycine and proline residues in these proteins following helix 1, which would be disruptive to secondary structures ( Fig 5C) .
The hotspots for pRab8a:RILPL2 interactions, as gleaned from cellular interactions with RILPL2 mutants, are shown with circles above the sequences of RILP family proteins ( Fig 5C) . The red circles denote essential residues for recognition of pRab8a(GTP) and are mostly conserved in the phospho-Rab binding domains. R139 RL2 mutations have modest effects on Rab8a recognition (Figs 3 and EVFig3), and are not conserved (blue circle). P131 RL2 is variable in this family and the mutant P131A RL2 does not affect binding, suggesting that sequence variability is possible within the X-cap.
Interestingly, LRRK1 phosphorylation of Rab7 at Ser72 (switch 2) has recently been shown to promote interactions with RILP [17] . The RILP construct used for recombinant expression begins at C241 and the PDB file (1yhn) for the complex RILP:Rab7 contains the co-ordinates for RILP beginning at S244 (T134 RL2 ). It is possible that an X-cap could form and bind to pS72 (Rab7) given a modest extension of the RILP polypeptide toward the N-terminus to stabilize backbone anti-parallel hydrogen bonds. Although RILP lacks a positive residue (Q240), the structure of pRab8a:RILPL2 reveals that Arg130 RL2 is distant from pT72 and may be tolerated as a glutamine within a possible X-cap in the RILP:pRab7 complex.
Sequence comparisons suggest that two other scaffolding proteins previously implicated in JNK signaling, namely JIP3 [27] and JIP4 [28] , likely possess a phospho-Rab binding domain ( Fig 5C) . These proteins have key residues equivalent to R130 RL2 , R132 RL2 and K149 RL2 in their putative phospho-Rab binding domain ( Fig 5C) . We therefore tested whether full length JIP3 or JIP4 would bind to LRRK2-phosphorylated Rab8a or Rab10 in cells employing the co-expression assay utilized above to assess interaction of pRab8a with RILPL2 ( Fig 5D and EVFig5) . These results revealed that both JIP3 and JIP4 specifically associated with LRRK2-phosphorylated Rab10. Addition of MLi-2 ablated interaction of JIP3 and JIP4 with Rab10 consistent with the interaction being phosphorylation dependent ( Fig 5D) . In contrast, a weak interaction just above background was observed between Rab8a and JIP3/4, which was not dependent upon phosphorylation by LRRK2 ( Fig EVFig5) . This emphasizes that phospho-Rab binding domains are likely to display selectivity for different phosphorylated Rab proteins.
Further work is required to identify which sets of phospho-Rab proteins interact with JIP3/4 and how specificity for Rab GTPases is achieved.
In summary, the crystal structure of pRab8a in complex with RILPL2 provides molecular details of how post-translational modifications of Rab GTPases enable effector specificity. The structure reveals a positively charged X-cap at the N-termini of the RILPL2 -helical dimer that mediates interactions with phosphothreonine in switch 2.
The residue pT72 is situated within the switch/interswitch region and thus provides a means of tuning the strength of interactions with GAPs, GEFs and other effectors to regulate membrane trafficking upon LRRK2 activation in cells.
Materials and Methods

Protein expression and purification
The cDNA for Rab8a (residues 1-181, Q67L) lacking the flexible C-terminal tail was ordered from Genscript in a codon-optimized form to enable E.coli expression. The cDNA was cloned into pET28a at the NdeI/BamH1 sites for both of these constructs. The
Rab8a wildtype (WT) construct was made by site directed mutagenesis using the Fig S1) .
Phosphorylation of Rab8a
It has recently been shown that the MST3 kinase can specifically and efficiently phosphorylate Rab8a at Thr72 in vitro (Vieweg, S et al manuscript in preparation). As MST3 is much easier to express than LRRK2, we decided to phosphorylate Rab8a at T72 confirmed by PhosTag gel electrophoresis. In order to stabilize pRab8a, the pH was adjusted to pH 7.5 immediately after elution from the ion-exchange column.
Crystallization, data collection and refinement
Crystals of pRab8(Q67L): His 6 -RL2 complex were obtained in a 1:1 molar ratio of protein:peptide at a total of 12 mg/mL. Crystals were grown in 100 mM HEPES buffer (pH 7), 10% PEG4,000, and 10% 2-propanol. Plate-like crystals were harvested in precipitant supplemented with 25% glycerol and stored frozen in liquid nitrogen. X-ray data were collected under a cryogenic nitrogen stream at 100K (beamline 24-ID-C, Advanced Photon Source).
Native diffraction data were reduced using XDS and aimless, followed by structure determination using the Phaser software in the PHENIX package [29, 30] .
Initial rounds of molecular replacement using Rab8a (GppNHp, PDB code 4lhw) resulted in a solution for 2 molecules in the asymmetric unit. Following successful identification of Rab8a in the crystal lattice, the electron density for the coiled coil of the effector was apparent. Side chains for RILPL2 were clear in the initial electron density, and refinement was performed using multiple rounds of model building and energy minimization using PHENIX and COOT [31] . 
Structural analyses and superpositions
In general, structures were aligned using the 'secondary structure matching'
(SSM) protocol in COOT. The backbone superpositions of Rab8a from multiple structures (complexed, uncomplexed) typically aligned with an RMSD of 0.4 Å. The heterotetrameric structures of Rab8a:RILPL2 and Rab7:RILP were aligned using the Superpose software in CCP4 [32, 33] . In order to better visualize the relative positions of the effectors, secondary structures from all 4 molecules in each complex were aligned. A total of 330 residues were matched, including 21 residues from each chain of RILP and RILPL2. The overall RMSD for the backbone atoms was approximately 3 Å.
Pulldown assays and isothermal titration calorimetry
Calorimetry was performed in triplicate on an ITC-200 instrument (GE Healthcare).
Protein concentrations were calculated based on their Abs 280 using a ND-1000 NanoDrop spectrophotometer (Thermo Scientific). Following purification of Rab8a, the protein was dialyzed together in the same buffer as RILPL2 (10 mM Tris-HCl, 300 mM NaCl, 5 mM 
Plasmids for cellular assays
The plasmids used for co-immunoprecipitation experiments were acquired from MRC 
Antibody reagents
Antibodies used in this study were diluted in 5% w/v bovine serum albumin in TBS supplemented with 0.1% Tween-20 and 0.03% w/v sodium azide. The Rabbit monoclonal antibody for total LRRK2 (N-terminus) was purified at the University of Dundee [34] . Values in parentheses in the column on right correspond to the statistics in the highest resolution bin. RMSD, root-mean-square deviation. Rmerge =  hkl  j I hkl,j -<I hkl >/ hkl  jhkl,j 
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